SCHEMBL5161345

SCHEMBL5161345

O=C(CC(=O)N1CCCCC1)c1ccoc1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.43
RAB9A P51151 4/20 0.43
CYP3A4 P08684 1/20 0.42
ALDH1A1 P00352 5/20 0.41
HPGD P15428 5/20 0.41
NPC1 O15118 3/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
CHRNB2 P17787 1/20 0.39
CHRNB4 P30926 1/20 0.39
CHRNA3 P32297 1/20 0.39
CHRNA7 P36544 1/20 0.39
CHRNA4 P43681 1/20 0.39
LMNA P02545 1/20 0.39
GAA P10253 1/20 0.38
TSHR P16473 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5159949 0.98 TRPA1 (0.44) TRPA1RAB9ACYP3A4ALDH1A1HPGD
SCHEMBL29944401 0.78 HPGD (0.62) CYP3A4ALDH1A1HPGDCHRNB2CHRNB4
SCHEMBL6692694 0.77 HPGD (0.59) RAB9ACYP3A4ALDH1A1HPGDNPC1
SCHEMBL28159515 0.76 HPGD (0.59) ALDH1A1HPGDCHRNB2CHRNB4CHRNA3
SCHEMBL5160900 0.74 PLOD2 (0.51) RAB9ACYP3A4ALDH1A1HPGDSMN1; SMN2
SCHEMBL5158586 0.72 PLOD2 (0.53) RAB9ACYP3A4ALDH1A1HPGDSMN1; SMN2
SCHEMBL4995985 0.72 TRPA1 (0.53) TRPA1RAB9ACYP3A4ALDH1A1HPGD
SCHEMBL5160787 0.72 HPGD (0.41) RAB9AALDH1A1HPGDNPC1SMN1; SMN2
SCHEMBL5163607 0.72 CES2 (0.43) RAB9AALDH1A1HPGDNPC1SMN1; SMN2
SCHEMBL5158705 0.72 RAB9A (0.68) RAB9AALDH1A1NPC1SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293899-B2 Ketone transfer hydrogenation of stereoisomerically enriched 3-heteroaryl-3-oxocarboxylic esters by reducing 3-heteroaryl-3-hydroxycarboxylic esters in the presence of a ruthenium-containing catalyst, an amine and formic acid and/or formates LANXESS DEUTSCHLAND GMBH (DE) 2012-10-23 US disclosed
EP-1340746-B1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives SALTIGO GMBH (DE) 2007-02-28 EP disclosed
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives LANXESS DEUTSCHLAND GMBH (DE) 2003-12-04 US disclosed
EP-1340746-A1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives BAYER AG (DE) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives GRHPR, HPD, HAAO TRPA1 4224/4885RAB9A 3428/4885CYP3A4 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.